Evidence map›Paper›PMID 32723556›Full record

Observational studyThe American journal of cardiology2020

Impact of Diabetes Mellitus on Stroke and Survival in Patients With Atrial Fibrillation.

Sri Harsha Patlolla, Hon-Chi Lee, Peter A Noseworthy, Waldemar E Wysokinski, David O Hodge, Eddie L Greene, Bernard J Gersh, Rowlens M Melduni

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in The American journal of cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The Role of Diabetes and SGLT2 Inhibitors in Cerebrovascular Diseases.Current neurology and neuroscience reports · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Sri Harsha PatlollaDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Hon-Chi LeeDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Peter A NoseworthyDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Waldemar E WysokinskiDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
David O HodgeBiostatistics Unit, Mayo Clinic, Jacksonville, Florida.
Eddie L GreeneDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester.
Bernard J GershDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Rowlens M MelduniDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: melduni.rowlens@mayo.edu.
Mayo Clinic · USJacksonville College · US

Funding

The Role of Autoimmune Mechanisms in the Pathogenesis of Atrial FibrillationK01HL135288 · NHLBI · MAYO CLINIC ROCHESTER · PI MELDUNI, ROWLENS MICHEL · 2017 to 2021
$854k
NHLBI NIH HHS K01 HL135288
6 · The paper itself

Abstract

Although diabetes mellitus (DM) has been established as a risk factor for developing atrial fibrillation (AF) and is a known risk factor for stroke, it is unclear whether the presence or duration of DM is the primary adverse influence on the clinical course of AF. We retrospectively analyzed patients diagnosed with incident AF to examine the impact of DM on ischemic stroke and all-cause mortality. The diagnosis of DM was established by ICD-9 codes and review of medical records. To account for the significant differences in baseline characteristics of patients with and without diabetes, we matched 909 AF patients with DM with 909 AF patients without DM using propensity score matching based on 26 baseline variables. Cox regression analysis was used to identify independent factors associated with ischemic stroke and mortality. The mean age of the propensity matched cohort was 74 ± 11.5 years and 55.4% were male. Over a median follow-up period of 5.4 years (maximum 23.9 years), cumulative survival was significantly lower for patients with DM than those without DM; Log-rank p <0.001. In the propensity-matched comparison, the risk of mortality was significantly higher in the DM group compared with the non-DM group (hazard ratio 1.25; 95% confidence interval 1.12 to 1.69; p <0.001). Likewise, patients with DM had a higher risk of stroke (hazard ratio 1.32; 95% confidence interval 1.02 to 1.69; p = 0.03). Duration of DM was not associated with increased risk for stroke or mortality. In conclusion, the co-morbidity of DM represents an independent predictor of reduced survival and further highlights the excess risk of thromboembolism in patients with AF.

Indexed as

AgedAtrial FibrillationCause of DeathDiabetes ComplicationsFemaleHumansMaleMinnesotaPropensity ScoreRetrospective StudiesRisk FactorsStroke

Identifiers

PMID32723556
PMCPMC7484039
OpenAlexW3038416353

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.